An ongoing trial studying PSMA-PET in breast cancer as a biomarker of androgen resistance in HER2-negative, AR-positive breast cancer is ongoing (NCT04573231), noting such an association in prostate cancer. This evidence concerns the gene ERBB2 and breast cancer.